"Breast Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the human BREAST.
| Descriptor ID |
D001943
|
| MeSH Number(s) |
C04.588.180 C17.800.090.500
|
| Concept/Terms |
Breast Neoplasms- Breast Neoplasms
- Breast Neoplasm
- Neoplasm, Breast
- Breast Tumors
- Breast Tumor
- Tumor, Breast
- Tumors, Breast
- Neoplasms, Breast
Breast Carcinoma- Breast Carcinoma
- Breast Carcinomas
- Carcinoma, Breast
- Carcinomas, Breast
Mammary Neoplasms, Human- Mammary Neoplasms, Human
- Human Mammary Neoplasm
- Human Mammary Neoplasms
- Neoplasm, Human Mammary
- Neoplasms, Human Mammary
- Mammary Neoplasm, Human
Breast Cancer- Breast Cancer
- Cancer, Breast
- Mammary Cancer
- Cancer, Mammary
- Cancers, Mammary
- Mammary Cancers
- Malignant Neoplasm of Breast
- Breast Malignant Neoplasm
- Breast Malignant Neoplasms
- Malignant Tumor of Breast
- Breast Malignant Tumor
- Breast Malignant Tumors
- Cancer of Breast
- Cancer of the Breast
|
Below are MeSH descriptors whose meaning is more general than "Breast Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Breast Neoplasms".
This graph shows the total number of publications written about "Breast Neoplasms" by people in this website by year, and whether "Breast Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 12 | 2 | 14 |
| 1997 | 21 | 4 | 25 |
| 1998 | 25 | 5 | 30 |
| 1999 | 16 | 1 | 17 |
| 2000 | 15 | 7 | 22 |
| 2001 | 16 | 4 | 20 |
| 2002 | 11 | 6 | 17 |
| 2003 | 32 | 9 | 41 |
| 2004 | 25 | 7 | 32 |
| 2005 | 55 | 5 | 60 |
| 2006 | 45 | 7 | 52 |
| 2007 | 36 | 3 | 39 |
| 2008 | 38 | 6 | 44 |
| 2009 | 49 | 11 | 60 |
| 2010 | 57 | 11 | 68 |
| 2011 | 53 | 11 | 64 |
| 2012 | 46 | 6 | 52 |
| 2013 | 63 | 14 | 77 |
| 2014 | 58 | 12 | 70 |
| 2015 | 93 | 9 | 102 |
| 2016 | 60 | 11 | 71 |
| 2017 | 65 | 8 | 73 |
| 2018 | 78 | 4 | 82 |
| 2019 | 56 | 7 | 63 |
| 2020 | 63 | 13 | 76 |
| 2021 | 69 | 6 | 75 |
| 2022 | 61 | 1 | 62 |
| 2023 | 60 | 2 | 62 |
| 2024 | 47 | 4 | 51 |
| 2025 | 49 | 4 | 53 |
| 2026 | 6 | 0 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Breast Neoplasms" by people in Profiles.
-
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer. Cancer Res. 2026 Apr 02; 86(7):1707-1723.
-
Novel risk score for predicting acute cardiovascular and cerebrovascular events after chest radiotherapy in patients with breast or lung cancer. Eur J Prev Cardiol. 2026 Mar 13; 33(4):513-525.
-
MiR-200c restoration inhibits FOXP3 and metastatic spread in breast cancer: evidence from in vitro and in vivo models. BMC Cancer. 2026 Feb 14; 26(1).
-
Guideline-concordance along the cancer care continuum and breast cancer mortality by race and ethnicity: a SEER-Medicare study. Cancer Causes Control. 2026 Jan 21; 37(2):33.
-
Multiomic Factor Analysis for Pathologic Complete Response after Pembrolizumab + Trastuzumab + Pertuzumab in HER2-Enriched Early Breast Cancer: WSG-Keyriched-1 Trial. Clin Cancer Res. 2026 Jan 06; 32(1):214-223.
-
Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer. CA Cancer J Clin. 2026 Jan-Feb; 76(1):e70055.
-
17?-Hydroxysteroid dehydrogenases 1 and 2: potential markers for breast cancer recurrence and tamoxifen resistance among premenopausal women diagnosed with breast cancer in Denmark. Breast Cancer Res. 2025 Dec 30; 28(1):28.
-
Interventions to improve adherence to oral endocrine therapy for prevention or treatment of breast cancer in Black women of low socioeconomic status. Support Care Cancer. 2025 Dec 11; 34(1):24.
-
Identification of factors associated with non-adherence to oral endocrine therapy in breast cancer patients of low socioeconomic status: a single centre retrospective study. Int J Clin Pharm. 2026 Feb; 48(1):266-273.
-
Trastuzumab Deruxtecan plus Pertuzumab for HER2-Positive Metastatic Breast Cancer. N Engl J Med. 2026 Feb 05; 394(6):551-562.